

Ardea Biosciences, Inc./DE  
Form 8-K  
October 19, 2009

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934  
Date of Report (Date of earliest event reported): **October 19, 2009**  
**Ardea Biosciences, Inc.**  
(Exact name of registrant as specified in its charter)**

**Delaware**

**1-33734**

**94-3200380**

(State or other jurisdiction  
of incorporation)

(Commission  
File Number)

(IRS Employer  
Identification No.)

**4939 Directors Place  
San Diego, California**

**92121**  
(Zip Code)

(Address of principal executive offices)

Registrant's telephone number, including area code: **(858) 652-6500**  
**Not applicable.**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 7.01. Regulation FD Disclosure

Item 9.01. Financial Statements and Exhibits

SIGNATURE

EXHIBIT LIST

EX-99.1

EX-99.2

---

**Table of Contents**

**Item 7.01. Regulation FD Disclosure**

A copy of presentation materials describing the Company's business to be used by the Company at a scientific presentation and from time to time thereafter is filed as Exhibit 99.1 hereto. These materials reflect updates to information previously furnished by the Company regarding the Company's research and development programs, including information relating to expected research and development milestones. The Company does not intend to file any update of these presentation materials in the future. The fact that these updated presentation materials are being furnished should not be deemed an admission as to the materiality of any information contained in the materials. The Company has recently received and publicly announced certain clinical data related to its products. A copy of the press release announcing the data and a related live conference call and webcast to discuss the data is filed as Exhibit 99.2 to this Form 8-K and is incorporated herein by reference in its entirety.

The information in this Item 7.01 and Exhibits 99.1 and 99.2 attached hereto shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits. The following material is filed as an exhibit to this Current Report on Form 8-K:

**Exhibit**

**Number Document Description**

99.1 Ardea Biosciences, Inc. presentation materials date as of October 19, 2009, and to be used from time to time thereafter.

99.2 Press release dated October 19, 2009.

---

**Table of Contents**

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**ARDEA BIOSCIENCES, INC.**

Date: October 19, 2009

/s/ JOHN W. BECK  
John W. Beck  
Chief Financial Officer

---

**Table of Contents**

**EXHIBIT LIST**

<b>Exhibit Number</b>	<b>Document Description</b>
99.1	Ardea Biosciences, Inc. presentation materials updated as of October 19, 2009, and to be used from time to time thereafter.
99.2	Press release dated October 19, 2009.